Next Article in Journal
Clinicopathological Appearance of Epidermal Growth-Factor-Containing Fibulin-like Extracellular Matrix Protein 1 Deposition in the Lower Gastrointestinal Tract: An Autopsy-Based Study
Previous Article in Journal
Function and Global Regulation of Type III Secretion System and Flagella in Entomopathogenic Nematode Symbiotic Bacteria
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Luis Miguel Juárez-Salcedo
Santosh Nimkar
Ana María Corazón
3 and
Samir Dalia
Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain
College of Osteopathic Medicine, Kansas City University, Kansas City, MO 64804, USA
Primary Care Medicine, Adelfas Primary Care Center, 28007 Madrid, Spain
Hematology/Oncology Department, Mercy Clinic Oncology and Hematology, Joplin, MI 73120, USA
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(14), 7580;
Submission received: 27 May 2024 / Revised: 3 July 2024 / Accepted: 6 July 2024 / Published: 10 July 2024
(This article belongs to the Special Issue Antibody Therapy for Hematologic Malignancies)


Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.

1. Background

DLBCL is the seventh most common cancer in the general population and the most common hematological malignancy, occurring in approximately 30% of all cases of non-Hodgkin’s lymphoma [1]. Currently, immunochemotherapy treatment with the addition of the monoclonal antibody rituximab to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) achieves high cure rates of about 60–65% of cases [2]. However, 10–15% of patients treated with R-CHOP are primary refractory (incomplete response or relapse in the first 6 months after treatment) [3,4]. This population achieves overall response rates (ORR) of 26% and complete response rates (CR) of 7%, with a median survival of 6.3 months [5].
Despite advances in the initial treatment of this type of high-grade lymphoma, therapeutic options in relapsed/refractory patients are limited. In fit transplant-eligible patients, treatment includes high-dose chemotherapy followed by autologous hematopoietic cell transplantation. However, only half of these patients respond to initial salvage therapy, and the overall cure rate is 35–45% after autologous transplantation [6,7].
The management of non-transplant candidates who fail to respond to salvage therapy and those who relapse after autologous bone marrow transplantation is challenging. For a long time, the only viable options included single-agent or low-dose multi-agent chemotherapy with palliative intent. Today, new therapeutic options have emerged that include immunotherapy and cell therapy.
DLBCL is a heterogeneous disease, with different clinical, morphologic, and immunohistochemical features depending on the subtype. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (named double hit or triple hit) is clinically aggressive, with poor prognosis and low survival rates. Similarly, double- or triple-expressing lymphomas, as well as high-grade lymphoma transformed from indolent lymphoma or presence of TP53 mutation/deletion, are associated with poor prognosis [8]. In these subgroups, standard therapy has inferior efficacy and there is an urgent need to identify effective and well-tolerated therapeutic alternatives.
In recent years, new molecules and therapies have appeared on the scene in the treatment of relapsed or refractory DLBCL. These alternatives seek to bring some hope to the dark outlook for survival in this type of patient.
The most important advance in recent years has been CD19-targeted chimeric antigen receptor-modified T-cell (CART) therapy [9]. In 2017, this therapy gained Food and Drug Administration (FDA) approval for treatment of relapsed refractory DLBCL due to durable response rates in approximately 40% of recipient patients. However, this therapy is not without serious side effects, such as cytokine release syndrome or neurological toxicity [10].
Novel monoclonal antibodies, bispecific antibodies against T cells (BiTE), and antibody–drug conjugates (ADCs) are new therapeutic options that have appeared on the treatment horizon for these relapsed/refractory patients and are the focus of research attention. ADCs are immunoconjugated molecules consisting of a modified monoclonal antibody chemically linked to a cytotoxic drug by a stable chemical linker. The final molecule is able to precisely deliver a cytotoxic drug to the desired target cell, resulting in a greater effect on the tumor with fewer side effects [11].
After antigen binding, the antibody–drug conjugate (ADC) is internalized through the process of receptor-mediated endocytosis, followed by degradation of the linker and release of the cytotoxic molecule. Finally, direct DNA damage results in cell death through direct damage by the payload or through disruption of cellular processes such as tubulin polymerization and polypeptide synthesis.
Since 2009, the FDA has approved several treatments, including the CD79a-targeted ADC, polatuzumab vedotin-piiq, in combination with bendamustine and rituximab (Pola-BR) [12]. Other regimens including drugs such as Selinexor [13], an XPO1 inhibitor, have been approved since June 2020; tafasitamab-cxix, a humanized anti-CD19 monoclonal antibody, in combination with lenalidomide, received approval in July 2020 [14]. More recently, the ADC loncastuximab tesirine-lpyl was approved in April 2021 [15]. Several other drugs are in the pipeline for approval and others have already been approved for the management of this type of refractory lymphoma, including bispecific antibodies directed against CD20 (mosunetuzumab, glofitamab, odronextamab, epcoritamab) and ADCs such as denintuzumab mafadot targeting CD74 and inotuzumab ozogamicin targeting CD22 [16,17].
Loncastuximab tesirine is a two-component ADC, a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepinedimer toxin. This humanized IgG1 monoclonal antibody targets CD19, which is expressed on B-lymphocytes from pre-B to mature B-lymphocytes and is not normally expressed on other human cell lines [18,19,20]. This molecule was approved by the FDA in April 2021 for the treatment of R/R large B-cell lymphoma (including DLBCL arising by low-grade lymphoma) in adult patients after two or more lines of immune chemotherapy, based on LOTIS-2 data in 2020 [15].
Currently, the efficacy and safety of the use of this ADC in patients with R/R DLBCL has already been published by different working groups, either in monotherapy or in association with other drugs such as Ibrutinib. However, new combinations are being investigated with the aim of improving treatment options for this group of patients with few treatment alternatives.

2. Mechanism of Action

Loncastuximab tesirine (ADCT-402, also known as Zynlonta™) is an antibody–drug conjugate (ADC) consisting of a targeted monoclonal antibody, a linker, and a cytotoxic drug [21,22,23,24]. Its humanized IgG1 monoclonal antibody targets CD19, which is expressed on B cells from pre-B to mature B cells. The antibody is conjugated to a novel cytotoxic “warhead”, the alkylating agent pyrrolobenzodiazepine dimer (PBD), via a linker that enables cathepsin removal. The combination of the cytotoxic PBD alkylating agent and SG3199 is called tesirine [21]. Unlike traditional chemotherapy, an ADC such as loncastuximab tesirine has highly selective activity, limiting toxicity and improving tolerability (Figure 1).
After binding to human CD19, loncastuximab tesirine is internalized into the cell and delivers the PBD dimer into the cell [25]. These monomers bind in the DNA minor groove and form a single covalent aminal linkage to the exocyclic N2 amino group of guanine within purine–guanine–purine sequences. PBD dimers, formed by joining two PBD monomers together via an appropriate polymethylene tether, can produce two covalent bonds forming highly cytotoxic DNA inter-strand crosslinks, preventing the separation of opposing strands, thereby disrupting basic DNA processes such as replication and ultimately inducing cell death [20] (Figure 2).
In in vitro studies, a weak but clear negative correlation (r = −0.7, p = 0.024) was observed between cell surface CD19 density and IC50 values in each cell line. In contrast, no relationship was observed between cell surface CD19 density and the IC50 value of SG3199 (r = −0.44, p = 0.2), although it showed potent cytotoxicity against the cell lines tested, consistent with its non-targeted properties. In B-cell lymphoma, the in vitro activity of loncastuximab is related to the protein expression of its target on the cell surface (p < 0.05) and to the RNA level of its target (p < 0.001). Loncastuximab had a synergistic effect with idelalisib, venetoclax and bendamustine, providing a rationale for further clinical development of different combinations.
In terms of pharmacokinetics, after a single dose of 1.5 mg/kg loncastuximab tesirine, the half-lives of the PBD conjugated antibody and the total antibody were 10.4 days and 9.9 days, respectively, confirming that this molecule has excellent in vivo stability. The results of the different clinical studies (LOTIS-1, LOTIS-2, and LOTIS-3) showed that the pharmacokinetic exposure of the loncastuximab tesirine pyrrolobenzodiazepine-conjugated antibody and the total antibody were similar, and both showed good serum stability after the first dose and after dose reduction from 150 μg/kg to 75 μg/kg at the end of cycle 2, showing sustained exposure and moderate accumulation in the 3-week regimen [21,26].

3. Clinical Trial Data

The potential efficacy of loncastuximab tesirine (loncastuximab/ADCT-402/MT-2111) in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) was initially elucidated in the LOTIS-1 trial (NCT02669017) for relapsing/remitting B-cell Non-Hodgkin Lymphoma (r/r B-NHL). A total of 41.3% of these DLBCL patients had relapsed after a prior response to a therapy line and 57.1% had been refractory to the last therapy line [24].
Researchers found an overall response rate (ORR) of 54.9% (28 of 51) with a complete response rate (CRR) of 37.3% (19 of 51), and a partial response rate (PRR) of 17.6% (9 of 51) in patients with relapsed/refractory DLBCL (r/r DLBCL) that received doses of ≥120 µg/kg [24]. Overall survival (OS) and progression free survival were determined to be 10.1 months and 2.9 months, respectively [24].
The majority of these patients also had tumor regression (38 of 54; 70.4%) and, post-follow-up, had a durable response in patients with CR and a median duration of response (DOR) of 3.1 months in PR patients [24]. Loncastuximab had varying levels of effectiveness with a 69.2% ORR in patients that had response to their previous therapy line and a 32.4% response in patients refractory to their previous therapy line. When subdivided, 26.5% of refractory patients (9 of 34) had a CR, 38.5% of the relapsed patients (10 of 26) had a CR, and 16.7% of patients with bulky disease (1 of 6) had a CR [24]. With these largely encouraging preliminary results, further clinical trials began testing the efficacy of loncastuximab in r/r DLBCL.
The LOTIS-2 trial (NCT02669017) was the first major human study officially conducted to assess the effectiveness of loncastuximab in treating r/r DLBCL. A total of the 139 of the 182 patients (76%) in the LOTIS-2 trial had DLBCL that had failed a median of three prior treatments (range: 1–13) [23]. ORR was 42.3% (95% CI: 33.9 to 51.1) and greater in higher doses of loncastuximab with lower doses of 15–90 µg/kg achieving lower ORR (29.4% ORR) than the higher doses of 120–200 µg/kg (47.2% ORR) [23]. It took a median time of 43 days (range: 31–323 days) for all patients to achieve a CR or PR [23]. For the majority of patients, the initial dose led to response when assessed 6 weeks/2 cycles after the treatment was started [15]. The median DOR was 4.5 months (95% CI: 3.9 to 9.5), with doses in the range of 120 µg/kg to 200 µg/kg being able to achieve similar DOR outcomes [23]. Median PFS was 2.8 months (95% CI: 1.9 to 3.8) in DLBCL patients, which was below the median of 3.1 months (95% CI: 2.7 to 4.2) in all patients. Median OS of patients with DLBCL was 7.5 months (95% CI: 6 to 9.8), which was lower than the median for all patients at 8.3 months (95% CI: 1.1,7.8) [23].
When LOTIS-2 phase 2 was completed, loncastuximab had a response rate of 48.3% in patients with r/r DLBCL [15]. Following this trial, loncastuximab became the first antibody–drug conjugate (ABD) with pyrrolobenzodiazepine (PBD), with approval for single-agent activity in r/r DLBCL and high-risk subgroups but not with bulky disease [15]. A matching-adjusted indirect comparison of efficacy concluded that loncastuximab had a significantly higher overall response rate than standard chemoimmunotherapy (CIT) for DLBCL [27]. Retrospective analyses conducted on the LOTIS-2 trial also demonstrated that younger patients (<70) and older patients (>70) appeared to have similar responses across nearly all evaluated measures [24,28]. Long-term follow-ups for the LOTIS-2 trial were conducted in September 2022, and maintained the durable responses found at the outset of LOTIS-2 phase 2 [29]. The ORR for DLBCL patients receiving loncastuximab remained the same, long-term, at 48.3% (70/145), as did the median OS and median PFS at 9.5 and 4.9 months, respectively [29]. Median DOR increased to 13.4 months. One patient with PR ended up having CR, which further increased the overall CRR to 24.8%. Of the 37 patients achieving CR, 31% and 44% were event-free for ≥1 and ≥2 years, respectively [29]. Though it remains to be seen if improved event free survival has any impact on OS and mortality, 11 of the patients that achieved CR had no evidence of disease for ≥2 years and required no additional treatment, which likely was associated with an increase in quality of life [29].
Treatment-emergent adverse events (TEAEs) were documented throughout these LOTIS trials but were managed through pre-treatment dexamethasone, spironolactone-like diuretics, and sun exposure limitations, and remained mild to moderate in severity [15,29]. Nearly all patients experienced at least one TEAE (98.6%) and the most common ones were elevated gamma glutamyl transferase (GGT) levels (42%), neutropenia (40%), and thrombocytopenia (33%). In LOTIS-1, patients had a 36.4% chance (32 of 88) of experiencing a severe TEAE of any grade and an 8% chance (7 of 88) of having a TEAE with fatal outcome. Despite this, most patients were able to tolerate at least two cycles of treatment [24]. Researchers determined that no deaths due to TEAEs were attributable to loncastuximab and no secondary malignancy or myelodysplastic syndromes were reported [29].
Table 1 summarizes the survival data from the clinical studies that led to the approval of the use of Loncastuximab in monotherapy, as well as the results of the combined use of this drug.

4. Toxicity Profile

Regarding the safety profile, the main emerging adverse events included hematological toxicity, fatigue, nausea, and rash. Febrile neutropenia was infrequent. The most frequent grade ≥ 3 adverse events included neutropenia, thrombocytopenia, and elevated γ-glutamyl transpeptidase (GGT) in the absence of other signs of hepatic toxicity. Hematological and hepatic toxicity of grade ≥ 3 can be controlled by withholding the drug until resolution and subsequently reducing the dose by 50% if prolonged toxicity (>3 weeks) occurs [24]. Other side effects observed were fluid retention, including pleural effusions, peripheral oedema, and pericardial effusion, which were effectively reduced by including premedication with oral dexamethasone and diuretics with spironolactone. Presumably, these are related to the PBD payload, although the pathogenic mechanisms are still unclear and may be associated with direct vascular toxicity. Rash was also a frequent adverse event and occurred mainly in sun-exposed areas. There were no cases of tumor lysis syndrome or tumor exacerbation.

5. Future Clinical Trials

Future LOTIS trials will seek to expand the understanding of loncastuximab efficacy in DLBCL. LOTIS-3 (NCT03684694) assessed the pairing of loncastuximab and Ibrutinib in DLBCL patients. The preliminary results from the phase 2, open-label, single-arm study had an ORR of 57.1% (95% CI: 39.4% to 73.7%), overall CRR of 34.3% (95% CI: 19.1% to 52.2%), and median DOR of 5.49 months. However, there were different outcomes for non-germinal center b-cell-like DLBCL (non-GCB DLBCL) and GCB DLBCL groups, with non-GCB achieving a lower CRR. While the DLBCL cohorts had an ORR of 57.1%, 34% CRR, and 22% PRR, the non-GCB group had a 45% ORR and 27% CRR, and the GCB group had a 77% ORR and 46% CRR [30]. This trial was subsequently terminated by an unknown administrative decision. Not many clinical trials have been conducted as of yet outside of the umbrella of the LOTIS trials. A trial that is ongoing in the Beijing Cancer Hospital (ChiCTR2300072058) replicated the study design of LOTIS-2 in a Chinese population and has shown that loncastuximab has single agent efficacy with minimal safety concerns in Chinese patients with r/r DLBCL. Their phase 2, open-label, single-arm study found that loncastuximab had an ORR of 51.6% (95% CI: 38.7% to 64.2%), CRR of 23.4%, median DOR of 6.37 months, median PFS of 4.96 months, and median OS of 9.33 months [31].
The future clinical trials will attempt to further understand loncastuximab ’s efficacy in DLBCL (Table 2). LOTIS-5 (NCT04384484), which began in September 2020 and will continue recruiting into 2028, is assessing the pairing of loncastuximab and rituximab (loncastuximab-R) vs. the standard rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with r/r DLBCL. Preliminary results (around n ≤ 20 patients, as of now) from this phase 3 randomized controlled trial appear to show a durable response (ORR 80% [95% CI: 56.3% to 94.3%]; CRR 50% [95% CI: 27.2% to 72.8%]; PRR 30% [95% CI: 11.9% to 54.3%]; median DOR 8.02 months [95% CI: 3.19—not reached]; median PFS 8.31 months [95% CI: 4.53—not reached]) and no new safety concerns [32]. LOTIS-7 (NCT04970901) aims to investigate the efficacy of loncastuximab with various promising treatment agents including but not limited to glofitamab, mosunetuzumab, and polatuzumab vedotin in previously untreated DLBCL and will run from December 2021 to May 2027. The City of Hope Comprehensive Cancer trial (NCT05672251: January 2024–December 2024) is investigating the pairing of loncastuximab and mosunetuzumab in the treatment of r/r DLBCL. The M.D. Anderson Cancer Center is conducting a clinical trial (NCT05464719: Beginning September 2022–January 2026) to determine the efficacy of loncastuximab in patients that have achieved PR after CAR-T cell therapy. In the past, loncastuximab has shown favorable results in patients that had relapsed or had disease progression after CAR-T cell therapy [33]. Of the 13 patients in the LOTIS-2 trial that had previously had CAR-T cell therapy, 6 (46%) had responses to loncastuximab, with the median OS, PFS, and duration of response being 8.2, 1.4, and 8, respectively [33]. In patients with DLBCL that have relapsed from CAR-T cell therapy, chemotherapy was found to be ineffective [18,34]. This multicenter observational study concluded that when these patients received chemotherapy, none had CR, only 50% had PR, and the patients, overall, had poor survival metrics (6-month OS: 25% [95 CI: 11 to 59] [18,34]). There are also some case reports indicating that patients with DLBCL previously treated with loncastuximab achieved 50% ORR when given CAR-T cell therapy [18,35].

6. Conclusions

Loncastuximab tesirine is a promising new therapeutic option for the management of patients with relapsed or refractory DLBCL. It is currently being used in the third line of treatment. ADCs are a new class of drugs, which can deliver the active molecule directly to the target cells, thus minimizing toxicity. Compared to the cell therapy represented by CART therapy, molecules such as loncastuximab represent a suitable option by solving the problems related to the collection and processing of the targeted T cells. In addition, treatment failure represents a major clinical challenge. There are currently no comparative studies or randomized controlled trials that directly compare the efficacy and safety of loncastuximab tesirine with that of other treatments for patients with R/R DLBCL. However, the ongoing LOTIS-5 trial will reveal the efficacy of this molecule in combination with rituximab compared to immunochemotherapy in these patients. The possibility that loncastuximab can be administered in local hospitals represents an advantage (geographic, economic, social), compared to patients who are candidates for CART treatment and who require referral to more complex centers.
Further trials and follow-up studies will help to better assess its role, both in the first line and in early relapsing or refractory episodes.

Author Contributions

Writing—original draft preparation, L.M.J.-S., S.N. and A.M.C.; writing—review and editing, S.D. All authors have read and agreed to the published version of the manuscript.


This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.


  1. Sehn, L.H.; Salles, G. Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2021, 384, 842–858. [Google Scholar] [CrossRef] [PubMed]
  2. Coiffier, B.; Lepage, E.; Brière, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Gisselbrecht, C.; Van Den Neste, E.; Salles, G.; et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. N. Engl. J. Med. 2002, 346, 235–242. [Google Scholar] [CrossRef] [PubMed]
  3. Maurer, M.J.; Ghesquières, H.; Jais, J.-P.; Witzig, T.E.; Haioun, C.; Thompson, C.A.; Delarue, R.; Micallef, I.N.; Peyrade, F.; Macon, W.R.; et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 2014, 32, 1066–1073. [Google Scholar] [CrossRef] [PubMed]
  4. Cheson, B.D.; Horning, S.J.; Coiffier, B.; Shipp, M.A.; Fisher, R.I.; Connors, J.M.; Lister, T.A.; Vose, J.; Grillo-López, A.; Hagenbeek, A.; et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999, 17, 1244. [Google Scholar] [CrossRef] [PubMed]
  5. Crump, M.; Neelapu, S.S.; Farooq, U.; Van Den Neste, E.; Kuruvilla, J.; Westin, J.; Link, B.K.; Hay, A.; Cerhan, J.R.; Zhu, L.; et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood 2017, 130, 1800–1808. [Google Scholar] [CrossRef] [PubMed]
  6. Crump, M.; Kuruvilla, J.; Couban, S.; MacDonald, D.A.; Kukreti, V.; Kouroukis, C.T.; Rubinger, M.; Buckstein, R.; Imrie, K.R.; Federico, M.; et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J. Clin. Oncol. 2014, 32, 3490–3496. [Google Scholar] [CrossRef] [PubMed]
  7. Gisselbrecht, C.; Glass, B.; Mounier, N.; Gill, D.S.; Linch, D.C.; Trneny, M.; Bosly, A.; Ketterer, N.; Shpilberg, O.; Hagberg, H.; et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 2010, 28, 4184–4190. [Google Scholar] [CrossRef] [PubMed]
  8. Chapuy, B.; Stewart, C.; Dunford, A.J.; Kim, J.; Kamburov, A.; Redd, R.A.; Lawrence, M.S.; Roemer, M.G.M.; Li, A.J.; Ziepert, M.; et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 2018, 24, 679–690. [Google Scholar] [CrossRef] [PubMed]
  9. Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.B.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.O.; Siddiqi, T.; Lin, Y.; et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 2017, 377, 2531–2544. [Google Scholar] [CrossRef] [PubMed]
  10. Schuster, S.J.; Bishop, M.R.; Tam, C.S.; Waller, E.K.; Borchmann, P.; McGuirk, J.P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.R.; et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2019, 380, 45–56. [Google Scholar] [CrossRef] [PubMed]
  11. Chau, C.H.; Steeg, P.S.; Figg, W.D. Antibody-drug conjugates for cancer. Lancet 2019, 394, 793–804. [Google Scholar] [CrossRef] [PubMed]
  12. Sehn, L.H.; Herrera, A.F.; Flowers, C.R.; Kamdar, M.K.; McMillan, A.; Hertzberg, M.; Assouline, S.; Kim, T.M.; Kim, W.S.; Ozcan, M.; et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2020, 38, 155–165. [Google Scholar] [CrossRef] [PubMed]
  13. Kalakonda, N.; Maerevoet, M.; Cavallo, F.; Follows, G.; Goy, A.; Vermaat, J.S.P.; Casasnovas, O.; Hamad, N.; Zijlstra, J.M.; Bakhshi, S.; et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020, 7, e511–e522. [Google Scholar] [CrossRef] [PubMed]
  14. Salles, G.; Duell, J.; Barca, E.G.; Tournilhac, O.; Jurczak, W.; Liberati, A.M.; Nagy, Z.; Obr, A.; Gaidano, G.; André, M.; et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020, 21, 978–988. [Google Scholar] [CrossRef]
  15. Caimi, P.F.; Ai, W.; Alderuccio, J.P.; Ardeshna, K.M.; Hamadani, M.; Hess, B.; Kahl, B.S.; Radford, J.; Solh, M.; Stathis, A.; et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021, 22, 790–800. [Google Scholar] [CrossRef] [PubMed]
  16. McMillan, A. A new warhead in lymphoma therapy? Blood 2021, 137, 2568–2570. [Google Scholar] [CrossRef] [PubMed]
  17. Wolska-Washer, A.; Robak, P.; Smolewski, P.; Robak, T. Emerging antibody-drug conjugates for treating lymphoid malignancies. Expert Opin. Emerg. Drugs 2017, 22, 259–273. [Google Scholar] [CrossRef] [PubMed]
  18. Calabretta, E.; Hamadani, M.; Zinzani, P.L.; Caimi, P.; Carlo-Stella, C. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. Blood 2022, 140, 303–308. [Google Scholar] [CrossRef] [PubMed]
  19. Liu, D. Cancer biomarkers for targeted therapy. Biomark. Res. 2019, 7, 25. [Google Scholar] [CrossRef] [PubMed]
  20. Hartley, J.A. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin. Investig. Drugs 2011, 20, 733–744. [Google Scholar] [CrossRef] [PubMed]
  21. Zammarchi, F.; Corbett, S.; Adams, L.; Tyrer, P.C.; Kiakos, K.; Janghra, N.; Marafioti, T.; Britten, C.E.; Havenith, C.E.G.; Chivers, S.; et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 2018, 131, 1094–1105. [Google Scholar] [CrossRef] [PubMed]
  22. Jain, N.; Stock, W.; Zeidan, A.; Atallah, E.; McCloskey, J.; Heffner, L.; Tomlinson, B.; Bhatnagar, B.; Feingold, J.; Ungar, D.; et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020, 4, 449–457. [Google Scholar] [CrossRef] [PubMed]
  23. Hamadani, M.; Radford, J.; Carlo-Stella, C.; Caimi, P.F.; Reid, E.; O’connor, O.A.; Feingold, J.M.; Ardeshna, K.M.; Townsend, W.; Solh, M.; et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 2021, 137, 2634–2645. [Google Scholar] [CrossRef] [PubMed]
  24. Kahl, B.S.; Hamadani, M.; Radford, J.; Carlo-Stella, C.; Caimi, P.; Reid, E.; Feingold, J.M.; Ardeshna, K.M.; Solh, M.; Heffner, L.T.; et al. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin. Cancer Res. 2019, 25, 6986–6994. [Google Scholar] [CrossRef] [PubMed]
  25. Ahmed, N.; Hamadani, M. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Expert Rev. Anticancer Ther. 2021, 21, 1313–1320. [Google Scholar] [CrossRef] [PubMed]
  26. Furqan, F.; Hamadani, M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: A review of clinical data. Ther. Adv. Hematol. 2022, 13, 20406207221087511. [Google Scholar] [CrossRef] [PubMed]
  27. Hamadani, M.; Chen, L.; Song, Y.; Xu, M.K.; Liao, L.; Caimi, P.F.; Carlo-Stella, C. Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. Clin. Lymphoma Myeloma Leuk. 2022, 22, e738–e744. [Google Scholar] [CrossRef] [PubMed]
  28. Hamadani, M.; Spira, A.; Zhou, X.; Liao, L.; Chen, L.; Radford, J.; Ai, W.; Solh, M.; Ardeshna, K.M.; Hess, B.; et al. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv. 2024, 8, 93–98. [Google Scholar] [CrossRef] [PubMed]
  29. Caimi, P.F.; Ai, W.Z.; Alderuccio, J.P.; Ardeshna, K.M.; Hamadani, M.; Hess, B.; Kahl, B.S.; Radford, J.; Solh, M.; Stathis, A.; et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 2024, 109, 1184–1193. [Google Scholar] [CrossRef] [PubMed]
  30. Carlo-Stella, C.; Kwiatek, M.; Chung, M.; Móciková, H.; Bergua-Burgues, J.M.; Gao, S.; Grosicki, S.; Stathis, A.; Toupin, D.; Wang, Y.; et al. Lotis-5, an Ongoing Phase 3 Randomized Study of Loncastuximab Tesirine with Rituximab (lonca-R) Versus Immunochemotherapy in Patients with R/R Dlbcl. Hematol. Oncol. 2023, 41, 850–851. [Google Scholar] [CrossRef]
  31. Lin, N.; Sun, X.; Zhou, H.; Zou, L.; Zhou, K.; Liu, L.; Yang, H.; Hu, K.; Cai, Q.; Liu, Y.; et al. Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2023, 142 (Suppl. S1), 4469. [Google Scholar] [CrossRef]
  32. Kwiatek, M.; Grosicki, S.; Jiménez, J.L.; Mariño, S.F.P.; Snauwaert, S.; Kingsley, E.; Zacchetti, G.; Wang, Y.; Wang, L.; Depaus, J. ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL. Clin. Lymphoma Myeloma Leuk. 2023, 23, S439–S440. [Google Scholar] [CrossRef]
  33. Caimi, P.F.; Ardeshna, K.M.; Reid, E.; Ai, W.; Lunning, M.; Zain, J.; Solh, M.; Kahl, B.S.; Hamadani, M. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing after AntiCD19 CAR-T Cell Therapy. Clin. Lymphoma Myeloma Leuk. 2022, 22, e335–e339. [Google Scholar] [CrossRef] [PubMed]
  34. Alarcon Tomas, A.; Fein, J.A.; Fried, S.; Flynn, J.R.; Devlin, S.M.; Fingrut, W.B.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia 2023, 37, 154–163. [Google Scholar] [CrossRef] [PubMed]
  35. Thapa, B.; Caimi, P.F.; Ardeshna, K.M.; Solh, M.; Carlo-Stella, C.; Kahl, B.S.; Hamadani, M. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020, 4, 3850–3852. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Structure of Loncastuximab.
Figure 1. Structure of Loncastuximab.
Ijms 25 07580 g001
Figure 2. Mechanisms of action of Loncastuximab.
Figure 2. Mechanisms of action of Loncastuximab.
Ijms 25 07580 g002
Table 1. Completed loncastuximab clinical trials.
Table 1. Completed loncastuximab clinical trials.
TrialN=DosingOR (ORR)CR; PR
PFS; OS; Median DOR (Months)
LOTIS-1 (open-label, single-arm, phase 1 study) 1

633 × 3 Dose-escalation design to determine adequate dose≤90 µg/kg: 2 (20%)
120 µg/kg: 6 (54.5%)
150 µg/kg: 9 (60.0%)
200 µg/kg: 13 (52.0%)
≥120 µg/kg: 28 (54.9%)
≤90 µg/kg: 1; 1
120 µg/kg: 4; 2
150 µg/kg: 5; 4
200 µg/kg: 10; 3
≥120 µg/kg: 19; 9
20 (32.8%); 10 (16.4%)
2.9 *; 10.1
CR- not reached
150 µg/kg: 5.5
120 µg/kg: 4.9
200 µg/kg: 4.1
LOTIS-2 (multicenter, open-label, single-arm, phase 2 study) 2

150 µg/kg first 2 cycles
75 µg/kg for subsequent cycles, up to 1 year
70 (48.3%)
[95% CI: 39.9% to 56.7%]
35; 35

24.1% [95% CI: 17.5% to 31.9%] **; 24%
4.9 [95% CI: 2.9–8.3];
9.9 *** [95% CI: 6.7–11.5];
10.3 **** [95% CI: 6.9-not reached]
LOTIS-3 x (loncastuximab + Ibrutinib: Phase 2 open-label, single-arm study) 3

3560 µg/kg loncastuximab q3w for 2 cycles +
560mg/day Ibrutinib oral up to 1 year
(CR/PR/stable disease patients receive additional loncastuximab cycle 5,6,9,10)
20 (57.1%)
[95% CI: 39.4% to 73.7%]
12; 8

34.3% [95% CI: 19.1% to 52.2%]; 22.9% #
PFS not reported;
OS not reported;
5.49 [95% CI: 6.9- not reached
* This is a primary endpoint result. Secondary endpoint result: 7.5-month PFS [27]. ** This is a primary endpoint result. Secondary endpoint result: 24.8% CRR [15]. *** This is a primary endpoint result. Secondary endpoint result: 9.5-month OS [15]. **** This is a primary endpoint result. Secondary endpoint result: 13.4-month median DOR, median not reached [15]. # No CI was provided. x This study was terminated. 1 Data are from Kahl et al. 2019 [24]. 2 Data are from Caimi et al. 2021 [15]. 3 Data are from Carlo-stella et al. 2021 [30]. All remaining trial information can be found on the publicly available clinical trials government website.
Table 2. Ongoing loncastuximab clinical trials.
Table 2. Ongoing loncastuximab clinical trials.
TrialTrial Identification Number and Trial DatesN=Any Available Results
(loncastuximab + R-GemOx [rituximab–gemcitabine–oxaliplatin]) 1

September 2020–
~330 by trial end. Currently n ≤ 20Preliminary Data:
OR(ORR): 16/20 (80%)
[95% CI: 56.3% to 94.3%]
CRR; PRR: 50% [95% CI: 27.2% to 72.8%]; 30% [95% CI: 11.9% to 54.3%]
PFS; OS; Median DOR (months): 8.31 [95% CI: 4.53—not reached]; OS not reported; 8.02 [95% CI: 3.19—not reached]
LOTIS-7 (loncastuximab + various other agents including but not limited to polatuzumab vedotin, glofitamab, and mosunetuzumab for r/r DLBCL)NCT04970901

December 2021
May 2027
~n = 200
(which includes patients with r/r B-NHL, DLBLCL, HGBCL, FL, MZL)
Chinese Cancer Centers Trial
(Replication of LOTIS-2) 2

September 2021
Ongoing (unknown completion)
~n = 64
(as of 11 January 2023 data cutoff)
ORR: 51.6%
[95% CI: 38.7% to 64.2%]
CRR: 23.4%
[NO CI provided]
PFS; OS; Median DOR:
4.96; 9.33; 6.37
[NO CI provided]
MD Anderson
(loncastuximab as consolidation therapy in r/r DLBCL)

September 2022
January 2026
~n = 30
(As of February 2024)
City of Hope
(loncastuximab + mosunetuzumab for r/r DLBCL)

January 2024
December 2024
~n = 36
(As of February 2024)
1 Data are from Kwiatek et al. 2023 [32]. 2 Data are from Lin et al. 2023 [31]. All remaining trial information can be found on the publicly available clinical trials government website when the trial-specific identification number is entered.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Juárez-Salcedo, L.M.; Nimkar, S.; Corazón, A.M.; Dalia, S. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Int. J. Mol. Sci. 2024, 25, 7580.

AMA Style

Juárez-Salcedo LM, Nimkar S, Corazón AM, Dalia S. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences. 2024; 25(14):7580.

Chicago/Turabian Style

Juárez-Salcedo, Luis Miguel, Santosh Nimkar, Ana María Corazón, and Samir Dalia. 2024. "Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma" International Journal of Molecular Sciences 25, no. 14: 7580.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop